ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV® (enfortumab vedotin-ejfv), […]
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Welcome to First 90 Days, a series dedicated to examining how pharma executives are planning for success in their new roles. Today, we’re looking at Entact Bio’s CEO, Victoria Richon who stepped into the role to help the company, which launched in December, develop novel precision medications aimed at enhancing beneficial proteins to treat disease. […]
